115/10/27 19:00 - 20:30

-

線上課程

時段	主題	講師	主持人	上課地點
19:00~19:05	Opening		歐弘毅 醫師 成大附醫 內分泌代謝科
19:05~19:35	The Comprehensive Benefits of Dual SGLT Inhibition : Perspective of Endocrinologist	李宜螢 醫師 土城長庚 內分泌代謝科	歐弘毅 醫師 成大附醫 內分泌代謝科
19:35~20:05	The Comprehensive Benefits of Dual SGLT Inhibition : Perspective of Nephrologist	蔡明憲 醫師 新光醫院 腎臟內科	歐弘毅 醫師 成大附醫 內分泌代謝科
20:05~20:25	Panel Discussion	All	歐弘毅 醫師 成大附醫 內分泌代謝科
20:25~20:30	Closing		歐弘毅 醫師 成大附醫 內分泌代謝科

The Comprehensive Benefits of Dual SGLT Inhibition:Perspective of Endocrinologist
The management of type 2 diabetes mellitus (T2DM) has evolved from a glucose-centric approach to a comprehensive strategy focused on long-term organ protection and overall cardiometabolic health. As endocrinologists strive to optimize outcomes beyond HbA1c reduction, therapies that provide multidimensional benefits have become increasingly important in routine clinical practice.
Canagliflozin, a dual SGLT2/SGLT1 inhibitor, offers a distinctive mechanism of action by promoting urinary glucose excretion through SGLT2 inhibition while delaying intestinal glucose absorption via transient SGLT1 inhibition. This dual effect contributes to effective glycemic control, reductions in postprandial glucose excursions, and sustained improvements in metabolic parameters. In addition, canagliflozin has demonstrated favorable effects on body weight, blood pressure, and insulin resistance, addressing several key components of the cardiometabolic syndrome commonly associated with T2DM.
Beyond metabolic control, robust clinical evidence supports the role of canagliflozin in reducing the risk of cardiovascular events and slowing the progression of chronic kidney disease. These cardiorenal benefits have reshaped treatment paradigms, positioning SGLT inhibitors as foundational therapies for appropriate patients with T2DM, particularly those at elevated cardiovascular or renal risk.
This presentation will review the comprehensive clinical benefits of dual SGLT inhibition with canagliflozin from an endocrinologist’s perspective. Emphasis will be placed on its unique pharmacological profile, evidence-based cardiorenal protection, and its role in delivering integrated, patient-centered care. By addressing multiple pathophysiological pathways simultaneously, canagliflozin represents an important therapeutic option for improving both short- and long-term outcomes in patients with T2DM.

The Comprehensive Benefits of Dual SGLT Inhibition:Perspective of Nephrologist
From a nephrologist’s perspective, slowing chronic kidney disease progression is a critical priority in patients with type 2 diabetes. Canagliflozin has demonstrated robust renal protective effects, as evidenced in the CREDENCE trial, showing significant reductions in kidney failure, albuminuria progression, and renal-related outcomes. Through mechanisms including reduction of intraglomerular pressure via tubuloglomerular feedback, decreased hyperfiltration, and anti-inflammatory effects, SGLT2 inhibition plays a key role in nephroprotection. The additional SGLT1 inhibition may further contribute by improving glycemic variability and reducing metabolic stress. Importantly, canagliflozin provides benefits independent of glycemic control, reinforcing its role as a disease-modifying therapy. This session will focus on integrating dual SGLT inhibition into CKD management to achieve comprehensive renal and systemic protection.

線上課程

-

-

中華民國醫師公會全國聯合會
社團法人中華民國藥師公會全國聯合會專業1.2積分
中華民國糖尿病學會乙類0.5分
台灣內科醫學會1分
台灣專科護理師學會(專科)
《實際學分數以各醫學會實際通過為主，包含審查中之各醫學會學分》